<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/623C14B8-7424-410A-BA88-2C2D7BBFC2D5"><gtr:id>623C14B8-7424-410A-BA88-2C2D7BBFC2D5</gtr:id><gtr:name>Ozics</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Eastman Dental Institute</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/623C14B8-7424-410A-BA88-2C2D7BBFC2D5"><gtr:id>623C14B8-7424-410A-BA88-2C2D7BBFC2D5</gtr:id><gtr:name>Ozics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DF6B7A6A-68D1-44F3-9CB2-AE6416130148"><gtr:id>DF6B7A6A-68D1-44F3-9CB2-AE6416130148</gtr:id><gtr:firstName>Irwin</gtr:firstName><gtr:surname>Olsen</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/12527535-2F89-457C-B033-20AEA6FAD5D0"><gtr:id>12527535-2F89-457C-B033-20AEA6FAD5D0</gtr:id><gtr:firstName>Anne</gtr:firstName><gtr:otherNames>Margaret</gtr:otherNames><gtr:surname>Young</gtr:surname><gtr:orcidId>0000-0001-8485-2056</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/0ADC7E5A-6C66-49E0-B44B-278107A9033A"><gtr:id>0ADC7E5A-6C66-49E0-B44B-278107A9033A</gtr:id><gtr:firstName>Vehid</gtr:firstName><gtr:surname>Salih</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=EP%2FF019866%2F1"><gtr:id>E270BFCD-9AA8-4478-8A74-6B443A09D050</gtr:id><gtr:title>Development of new injectable, PolyGeneCaP composites for gene therapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/F019866/1</gtr:grantReference><gtr:abstractText>The aim of gene therapy is to treat patients who are born with inherited diseases by providing a normal gene to repair or replace the damaged or missing gene. Potential applications of gene therapy include well-known diseases such as haemophilia, cystic fibrosis, muscular dystrophy, some types of cancer and many other disorders where the defective genes are now being identified. Current procedures for the introduction of healthy genes into the cells of affected patients have relied primarily on the use of virus-derived 'carriers', but there is growing concern that these agents are not yet well enough understood and have the potential to be dangerous, even fatal. Unfortunately, alternative synthetic gene-delivery systems have thus far been inefficient and have had only very limited success. In this project we are proposing to develop a non-viral delivery system that has a specific healthy gene entrapped within a safe chemical particle. We plan to use a new method to convert these into very small 'nanoparticles' (called GeneCaP) that fully surround the gene and therefore protect it from breakdown and also enable it to get more readily into the patient's cells. To increase further the efficiency of gene entry, which has been one of the major problems in gene therapy, we will place the GeneCaP into a novel liquid (PolyGeneCaP) which can be injected. This will be designed so that it will rapidly solidify very close to the diseased organ and then degrade slowly, releasing the encased GeneCaP adjacent to the cell where the gene is needed to function. The 'model' disease which will be used in this proposal is called Sly Disease (Mucopolysaccharidosis Type VII), one of a large group of lysosomal gene defects which result in progressive mental and physical disability and are usually fatal at an early age. Illness occurs because the defective gene is unable to produce a particular lysosomal protein, which when restored in the presence of the healthy gene alleviates the disease. In this study we will, for the first time, measure and carefully correlate the properties of the DNA-containing particles and the ability of these new 'gene-drugs' to help correct the MPS VII disease, in order to be able to develop the optimal treatment strategies for a range of genetic diseases.</gtr:abstractText><gtr:fund><gtr:end>2010-09-07</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2008-04-08</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>218239</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ozics</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Development of novel bone cements</gtr:description><gtr:id>6793BC58-7DD9-4FD0-A009-407625646960</gtr:id><gtr:impact>Funding obtained to develop a new bone cement. Ozics funded a PhD student that helped in the characterisation of their new product Comp06. These studies involved assesment of setting chemistry, mechanical properties and in vivo work. 
 - see 
http://www.prlog.org/11712867-swiss-ozics-group-announces-ce-mark-for-the-compo6-tm-bone-reinforcement-composite.html</gtr:impact><gtr:partnerContribution>patent costs and suport of a studentship</gtr:partnerContribution><gtr:piContribution>We advised Ozics on how to make and then analysed a new injectable cement produced by a commercial manufacturer (Sci Pharm) for vertebroplasty</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Ozics group</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>Ozics</gtr:fundingOrg><gtr:fundingRef>Ozics</gtr:fundingRef><gtr:id>CC78AC23-7AD7-4E60-92B1-5656F70E4A15</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>99285</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC - Regional Centre London</gtr:description><gtr:fundingOrg>MRC Regional Centre London</gtr:fundingOrg><gtr:fundingRef>G0701855</gtr:fundingRef><gtr:id>5EB2293C-4216-4C44-9B37-176B2F27676D</gtr:id><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>535000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Healthcare partnership</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>ref EP/ I022341/1</gtr:fundingRef><gtr:id>F9F93C33-5C9A-46A9-88B0-E2F803E333E2</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>980000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Institute for Health Research (NIHR)</gtr:department><gtr:description>i4i</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>University College London Hospitals Charity (UCLH)</gtr:fundingOrg><gtr:fundingRef>II-LA-0214-20002</gtr:fundingRef><gtr:id>1B95F212-B2AA-4F28-9AA8-04621B2386FF</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>261751</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/F019866/1</gtr:fundingRef><gtr:id>5D704BE9-592D-4730-BC7B-583F4E9495C8</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Increased understanding of drug release mechanisms from solid materials has been developed further in recent studies to provide dental composites that provide release of antibacterial agents. This had lead to a new patent being filed on release of large polymeric antibacterial agents from crosslinked methacrylate based composites. Dental materials using the principles are now under commercial evaluation. These could reduce increasing problems and concerns associated with antibacterial resistance and antibiotic use in dentistry.</gtr:description><gtr:firstYearOfImpact>2012</gtr:firstYearOfImpact><gtr:id>C5AA5FC3-B262-438D-9BA6-0454F88A9FC4</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:sector>Healthcare</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>This patent describes various degradable and non degradable cements for tooth and bone repair that contain reactive calcium phosphate fillers</gtr:description><gtr:id>841F057E-0198-4376-9E58-9546CB0B40B9</gtr:id><gtr:impact>We currently have funding to optimise, manufacture and CE mark a product over the next three years</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO2008037991</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Formulations and Composites with reactive fillers</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>A range of degradable injectable polymeric adhesives were synthesized and their ability to set rapidly at body temperature upon blue light exposure proven. Upon placement of the set materials in water, degradation was shown to occur at rates that could be controlled by varying the adhesive chemistry. Combination of these adhesives with reactive calcium phosphates was shown to reduce the acidity of the degrading polymers and enhance compatibility with human cells. A model gene was included in the fluid adhesive and subsequently released from the set material over a period of several weeks. By additional inclusion of agents that promote uptake of the gene a material capable of transfecting cells over a prolonged period was obtained. These findings demonstrate the potential of the new materials for gene therapy.</gtr:description><gtr:exploitationPathways>The materials developed have potential for application in a wide range of controlled drug delivery applications. Previous work has focused upon release of small drug molecules but this study demonstrates their suitability for controlled release of larger biological species. The new materials are covered by a recently granted patent</gtr:exploitationPathways><gtr:id>7E2E63DC-4FC4-421F-AEBA-893D60EC3769</gtr:id><gtr:sectors><gtr:sector>Healthcare</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>A new bone cement for vertebroplasty (fixation of osteoporotic vertebra)</gtr:description><gtr:id>4AD75DAD-5EFC-46B3-B05A-5C8632C300C2</gtr:id><gtr:impact>This product is being sold by a new company</gtr:impact><gtr:stage>Market authorisation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Bone cement</gtr:title><gtr:type>Therapeutic Intervention - Medical Devices</gtr:type><gtr:url>http://www.ozics.com</gtr:url><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Guided tissue regeneration membranes are used to hold back soft tissue and allow bone to regenerate.</gtr:description><gtr:id>BF11B42F-6E15-48BB-A976-2BFDDCACF8DD</gtr:id><gtr:impact>The new materials in addition to the above function provide calcium and phosphate release as well as a small drug that can promote bone repair</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>On hold</gtr:status><gtr:title>periodontal membrane</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E02FB99A-539E-4B0C-BC6D-5B9358B9C3C7"><gtr:id>E02FB99A-539E-4B0C-BC6D-5B9358B9C3C7</gtr:id><gtr:title>Chemical, modulus and cell attachment studies of reactive calcium phosphate filler-containing fast photo-curing, surface-degrading, polymeric bone adhesives.</gtr:title><gtr:parentPublicationTitle>Acta biomaterialia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dae15e139378ae8a150276822e06dcfc"><gtr:id>dae15e139378ae8a150276822e06dcfc</gtr:id><gtr:otherNames>Abou Neel EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1742-7061</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B187AE34-A674-412E-91F2-D52BEDBAA36C"><gtr:id>B187AE34-A674-412E-91F2-D52BEDBAA36C</gtr:id><gtr:title>Cell attachment and response to photocured, degradable bone adhesives containing tricalcium phosphate and purmorphamine.</gtr:title><gtr:parentPublicationTitle>Acta biomaterialia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/94237ac61513ad8bbaf49f9e76d61806"><gtr:id>94237ac61513ad8bbaf49f9e76d61806</gtr:id><gtr:otherNames>Gellynck K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1742-7061</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5644137D-E133-4835-BA48-462B11F223FC"><gtr:id>5644137D-E133-4835-BA48-462B11F223FC</gtr:id><gtr:title>Reactive calcium-phosphate-containing poly(ester-co-ether) methacrylate bone adhesives: chemical, mechanical and biological considerations.</gtr:title><gtr:parentPublicationTitle>Acta biomaterialia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f76706732cc4158a7609b4aa9382a37e"><gtr:id>f76706732cc4158a7609b4aa9382a37e</gtr:id><gtr:otherNames>Zhao X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1742-7061</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/17117C00-46FE-4943-8726-35B403C73B83"><gtr:id>17117C00-46FE-4943-8726-35B403C73B83</gtr:id><gtr:title>Viscoelastic and biological performance of low-modulus, reactive calcium phosphate-filled, degradable, polymeric bone adhesives.</gtr:title><gtr:parentPublicationTitle>Acta biomaterialia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dae15e139378ae8a150276822e06dcfc"><gtr:id>dae15e139378ae8a150276822e06dcfc</gtr:id><gtr:otherNames>Abou Neel EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1742-7061</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BB06249D-CD51-4001-9DB8-4F7066990F70"><gtr:id>BB06249D-CD51-4001-9DB8-4F7066990F70</gtr:id><gtr:title>Chemical characterization of a degradable polymeric bone adhesive containing hydrolysable fillers and interpretation of anomalous mechanical properties.</gtr:title><gtr:parentPublicationTitle>Acta biomaterialia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3457936797ccbfd7d9ba22f0029cdf0e"><gtr:id>3457936797ccbfd7d9ba22f0029cdf0e</gtr:id><gtr:otherNames>Young AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1742-7061</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/F019866/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>E847DD9B-2053-4BC7-97A9-4213B185C968</gtr:id><gtr:percentage>65</gtr:percentage><gtr:text>Materials sciences</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>35</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>B30DC286-3309-48E2-A15D-BDF547057A33</gtr:id><gtr:percentage>35</gtr:percentage><gtr:text>Drug Formulation &amp; Delivery</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>561091A1-9FC9-4508-B1B2-2F3623E1FC9D</gtr:id><gtr:percentage>35</gtr:percentage><gtr:text>Materials Characterisation</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>063026C5-CD0B-48AB-82F3-6359499A95D4</gtr:id><gtr:percentage>30</gtr:percentage><gtr:text>Materials Synthesis &amp; Growth</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>